Skip to contentL
Lipella Pharmaceuticals Inc.
L
LIPOLipella Pharmaceuticals Inc. Q2 2025 · 10-Q
Revenue$86.73K$86.73K−36.4% vs Q2 2024 Net Income-$1.33M-$1.33MN/M vs Q2 2024 EPS Diluted-$0.31-$0.31N/M vs Q2 2024 Operating Income-$1,356,575N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipella Pharmaceuticals Inc. · CIK 1347242 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-1564.2%−866.3 pt vs Q2 2024
Net margin-1530.6%−843.0 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end